vs

Side-by-side financial comparison of FORWARD AIR CORP (FWRD) and Sarepta Therapeutics, Inc. (SRPT). Click either name above to swap in a different company.

FORWARD AIR CORP is the larger business by last-quarter revenue ($631.2M vs $369.6M, roughly 1.7× Sarepta Therapeutics, Inc.). FORWARD AIR CORP runs the higher net margin — -4.5% vs -111.5%, a 107.0% gap on every dollar of revenue. On growth, FORWARD AIR CORP posted the faster year-over-year revenue change (-0.3% vs -42.1%). Over the past eight quarters, FORWARD AIR CORP's revenue compounded faster (7.9% CAGR vs 1.4%).

Forward Air Corp is a leading North American asset-light logistics and transportation provider. It offers core services including expedited less-than-truckload freight delivery, final-mile logistics, intermodal transport, warehousing, and supply chain solutions, serving key sectors such as e-commerce, retail, manufacturing, and automotive across the U.S., Canada, and Mexico.

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

FWRD vs SRPT — Head-to-Head

Bigger by revenue
FWRD
FWRD
1.7× larger
FWRD
$631.2M
$369.6M
SRPT
Growing faster (revenue YoY)
FWRD
FWRD
+41.8% gap
FWRD
-0.3%
-42.1%
SRPT
Higher net margin
FWRD
FWRD
107.0% more per $
FWRD
-4.5%
-111.5%
SRPT
Faster 2-yr revenue CAGR
FWRD
FWRD
Annualised
FWRD
7.9%
1.4%
SRPT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FWRD
FWRD
SRPT
SRPT
Revenue
$631.2M
$369.6M
Net Profit
$-28.3M
$-412.2M
Gross Margin
Operating Margin
-0.5%
-111.4%
Net Margin
-4.5%
-111.5%
Revenue YoY
-0.3%
-42.1%
Net Profit YoY
22.2%
-359.2%
EPS (diluted)
$-0.90
$-3.92

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FWRD
FWRD
SRPT
SRPT
Q4 25
$631.2M
$369.6M
Q3 25
$631.8M
$370.0M
Q2 25
$618.8M
$513.1M
Q1 25
$613.3M
$611.5M
Q4 24
$632.8M
$638.2M
Q3 24
$655.9M
$429.8M
Q2 24
$643.7M
$360.5M
Q1 24
$541.8M
$359.5M
Net Profit
FWRD
FWRD
SRPT
SRPT
Q4 25
$-28.3M
$-412.2M
Q3 25
$-16.3M
$-50.6M
Q2 25
$-12.6M
$196.9M
Q1 25
$-50.6M
$-447.5M
Q4 24
$-36.4M
$159.0M
Q3 24
$-73.4M
$33.6M
Q2 24
$-645.4M
$6.5M
Q1 24
$-61.7M
$36.1M
Gross Margin
FWRD
FWRD
SRPT
SRPT
Q4 25
Q3 25
59.3%
Q2 25
70.3%
Q1 25
77.5%
Q4 24
Q3 24
78.7%
Q2 24
87.6%
Q1 24
85.9%
Operating Margin
FWRD
FWRD
SRPT
SRPT
Q4 25
-0.5%
-111.4%
Q3 25
2.4%
-27.9%
Q2 25
3.2%
22.5%
Q1 25
0.8%
-49.1%
Q4 24
12.0%
25.3%
Q3 24
3.5%
5.2%
Q2 24
-170.2%
-0.2%
Q1 24
-12.1%
9.7%
Net Margin
FWRD
FWRD
SRPT
SRPT
Q4 25
-4.5%
-111.5%
Q3 25
-2.6%
-13.7%
Q2 25
-2.0%
38.4%
Q1 25
-8.3%
-73.2%
Q4 24
-5.8%
24.9%
Q3 24
-11.2%
7.8%
Q2 24
-100.3%
1.8%
Q1 24
-11.4%
10.0%
EPS (diluted)
FWRD
FWRD
SRPT
SRPT
Q4 25
$-0.90
$-3.92
Q3 25
$-0.52
$-0.50
Q2 25
$-0.41
$1.89
Q1 25
$-1.68
$-4.60
Q4 24
$-1.69
$1.56
Q3 24
$-2.66
$0.34
Q2 24
$-23.47
$0.07
Q1 24
$-2.81
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FWRD
FWRD
SRPT
SRPT
Cash + ST InvestmentsLiquidity on hand
$106.0M
$939.6M
Total DebtLower is stronger
$1.7B
$829.0M
Stockholders' EquityBook value
$113.3M
$1.1B
Total Assets
$2.7B
$3.3B
Debt / EquityLower = less leverage
14.89×
0.73×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FWRD
FWRD
SRPT
SRPT
Q4 25
$106.0M
$939.6M
Q3 25
$140.4M
$851.0M
Q2 25
$95.1M
$800.1M
Q1 25
$116.3M
$522.8M
Q4 24
$104.9M
$1.4B
Q3 24
$136.6M
$1.2B
Q2 24
$84.9M
$1.5B
Q1 24
$152.0M
$1.4B
Total Debt
FWRD
FWRD
SRPT
SRPT
Q4 25
$1.7B
$829.0M
Q3 25
$1.7B
$140.5M
Q2 25
Q1 25
Q4 24
$1.1B
Q3 24
$1.2B
Q2 24
$1.2B
Q1 24
$1.7B
$1.2B
Stockholders' Equity
FWRD
FWRD
SRPT
SRPT
Q4 25
$113.3M
$1.1B
Q3 25
$139.8M
$1.3B
Q2 25
$151.8M
$1.4B
Q1 25
$154.6M
$1.1B
Q4 24
$201.7M
$1.5B
Q3 24
$226.1M
$1.2B
Q2 24
$283.8M
$1.1B
Q1 24
$926.1M
$961.2M
Total Assets
FWRD
FWRD
SRPT
SRPT
Q4 25
$2.7B
$3.3B
Q3 25
$2.8B
$3.5B
Q2 25
$2.8B
$3.7B
Q1 25
$2.8B
$3.5B
Q4 24
$2.8B
$4.0B
Q3 24
$3.1B
$3.6B
Q2 24
$3.1B
$3.4B
Q1 24
$4.0B
$3.2B
Debt / Equity
FWRD
FWRD
SRPT
SRPT
Q4 25
14.89×
0.73×
Q3 25
12.05×
0.11×
Q2 25
Q1 25
Q4 24
0.74×
Q3 24
1.01×
Q2 24
1.14×
Q1 24
1.81×
1.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FWRD
FWRD
SRPT
SRPT
Operating Cash FlowLast quarter
$131.2M
Free Cash FlowOCF − Capex
$127.6M
FCF MarginFCF / Revenue
34.5%
Capex IntensityCapex / Revenue
1.3%
1.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-307.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FWRD
FWRD
SRPT
SRPT
Q4 25
$131.2M
Q3 25
$52.7M
$-14.6M
Q2 25
$261.3M
Q1 25
$27.6M
$-583.4M
Q4 24
$-23.2M
$92.0M
Q3 24
$51.2M
$-70.7M
Q2 24
$-45.2M
$14.9M
Q1 24
$-51.7M
$-242.1M
Free Cash Flow
FWRD
FWRD
SRPT
SRPT
Q4 25
$127.6M
Q3 25
$48.6M
$-37.5M
Q2 25
$229.5M
Q1 25
$15.7M
$-627.1M
Q4 24
$-30.5M
$54.0M
Q3 24
$40.7M
$-108.0M
Q2 24
$-59.6M
$-14.2M
Q1 24
$-56.7M
$-274.5M
FCF Margin
FWRD
FWRD
SRPT
SRPT
Q4 25
34.5%
Q3 25
7.7%
-10.1%
Q2 25
44.7%
Q1 25
2.6%
-102.5%
Q4 24
-4.8%
8.5%
Q3 24
6.2%
-25.1%
Q2 24
-9.3%
-3.9%
Q1 24
-10.5%
-76.4%
Capex Intensity
FWRD
FWRD
SRPT
SRPT
Q4 25
1.3%
1.0%
Q3 25
0.7%
6.2%
Q2 25
0.8%
6.2%
Q1 25
1.9%
7.1%
Q4 24
1.1%
6.0%
Q3 24
1.6%
8.7%
Q2 24
2.2%
8.1%
Q1 24
0.9%
9.0%
Cash Conversion
FWRD
FWRD
SRPT
SRPT
Q4 25
Q3 25
Q2 25
1.33×
Q1 25
Q4 24
0.58×
Q3 24
-2.10×
Q2 24
2.31×
Q1 24
-6.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FWRD
FWRD

Omni Logistics Segment$359.8M57%
Network$183.9M29%
Intermodal Segment$50.2M8%
Truckload$41.6M7%

SRPT
SRPT

Pmo Products$202.5M55%
Elevidys$110.4M30%
Other$56.7M15%

Related Comparisons